Natco Pharma Q4 PAT may dip 26.8% to Rs 156.1 cr: ICICI Securities

Net Sales are expected to decrease by 18.5 percent Q-o-Q (up 36 percent Y-o-Y) to Rs 553.4 crore, according to ICICI Securities. Natco Pharma to report net profit at 156.1 crore down 26.8% quarter-on-quarter.

April 17, 2017 / 13:51 IST

live

bselive
nselive

Volume

Todays L/H

ICICI Securities has come out with its fourth quarter (January-March) earnings estimates for the Healthcare sector. The brokerage house expects Natco Pharma to report net profit at 156.1 crore down 26.8% quarter-on-quarter.

Net Sales are expected to decrease by 18.5 percent Q-o-Q (up 36 percent Y-o-Y) to Rs 553.4 crore, according to ICICI Securities.

Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to fall by 25.5 percent Q-o-Q (up 128.7 percent Y-o-Y) to Rs 211.5 crore.

Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

first published: Apr 17, 2017 01:51 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347